Reuters logo
BRIEF-Newron Pharmaceuticals says encouraging preliminary results of Phase IIA study with Evenamide
January 3, 2017 / 4:47 PM / a year ago

BRIEF-Newron Pharmaceuticals says encouraging preliminary results of Phase IIA study with Evenamide

Jan 3 (Reuters) - Newron Pharmaceuticals SPA -

* Newron Pharmaceuticals SPA - Newron announces encouraging preliminary results of its Phase IIA study with Evenamide in patients with schizophrenia

* Newron Pharmaceuticals SPA- Evenamide in range of 15-25 mg bid (30-50 mg/day) was well tolerated

* Newron Pharmaceuticals SPA - Study shows patients treated with Evenamide showed improvement on symptoms of schizophrenia assessed by PANSS

* Newron Pharmaceuticals SPA- Two patients in Evenamide group discontinued treatment due to AES: Seizure (n=1) and Atrial Fibrillation (n=1)

* Newron Pharmaceuticals SPA - Study found no evidence of worsening of extrapyramidal symptoms, abnormal ECG findings with Evenamide treatment, compared to placebo Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below